Search research articles
Contact Us
Filters
Showing results (81-90 of 84) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 84 results.
Vaccine
|
August 22, 2016
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine
Deborah M Money, Erin Moses, Sandra Blitz, et al.
Frontiers in Cellular and Infection Microbiology
|
April 17, 2023
Maternal vaginal microbiome composition does not affect development of the infant gut microbiome in early life
Scott J Dos Santos, Zahra Pakzad, Arianne Y K Albert, et al.
Lancet (London, England)
|
September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
S Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Lancet. Infectious Diseases
|
July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 84) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 84 results.
Vaccine
|
August 22, 2016
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine
Deborah M Money, Erin Moses, Sandra Blitz, et al.
Frontiers in Cellular and Infection Microbiology
|
April 17, 2023
Maternal vaginal microbiome composition does not affect development of the infant gut microbiome in early life
Scott J Dos Santos, Zahra Pakzad, Arianne Y K Albert, et al.
Lancet (London, England)
|
September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
S Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Lancet. Infectious Diseases
|
July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Page
of 9